Clinical Trial

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis

Study acronym: NemoBaby
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of the study is to assess the pharmacokinetics (PK) and safety of nemolizumab in pediatric participants (aged 6-23 months) with moderate-to-severe atopic dermatitis (AD) who are not adequately controlled with topical treatments.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-15
Trial Details
NCT Number NCT07660835
Lead Sponsor Galderma R&D
Conditions Moderate-to-Severe Atopic Dermatitis
Enrollment 35 participants
Start Date 2026-07-13
Primary Completion 2028-07-15 (estimated)
Study Completion 2028-07-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-14